NVO — Use of GLP-1 drugs like Ozempic for weight loss linked to eating disorders

A growing number of reports indicate a potential link between the use of popular GLP-1 drugs, such as Ozempic and Mounjaro, and the onset of serious eating disorders like anorexia. Some individuals, including those who were not overweight, have reportedly developed restrictive eating patterns after using the appetite-suppressing medications for cosmetic weight loss. Health experts are raising concerns as the drugs become more accessible through telehealth platforms.